Evading innate immunity in nonviral mRNA delivery: Don't shoot the messenger

Drug Discovery Today

Volumn 21, Issue 1, 2016, Pages 11-25

  Devoldere, Joke ^a   Dewitte, Heleen ^a   De Smedt, Stefaan C ^a   Remaut, Katrien ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IN VITRO TRANSCRIBED MESSENGER RNA; INTERFERON; MESSENGER RNA; UNCLASSIFIED DRUG;

CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; IMMUNE EVASION; IMMUNOGENICITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; IN VITRO STUDY; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MAMMAL CELL; MOLECULAR RECOGNITION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEAR REPROGRAMMING; PROTEIN EXPRESSION; RECEPTOR BINDING; REGENERATIVE MEDICINE; REVIEW; VACCINATION; ANIMAL; GENE THERAPY; GENETICS; IMMUNOLOGY; PROCEDURES;

ANIMALS; GENETIC THERAPY; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; RNA, MESSENGER;

EID: 84960209149     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.07.009     Document Type: Review

References (149)

1. J.A. Wolff, and et al. Direct gene transfer into mouse muscle in vivo Science 247 1990 1465 1468
2. C. Leonhardt, and et al. Single-cell mRNA transfection studies: delivery, kinetics and statistics by numbers Nanomedicine 10 2014 679 688
3. S. Pascolo Vaccination with messenger RNA (mRNA) Handb. Exp. Pharmacol. 183 2008 221 235
4. G. Tavernier, and et al. mRNA as gene therapeutic: how to control protein expression J. Control. Release 150 2011 238 247
5. U. Sahin, and et al. mRNA-based therapeutics - developing a new class of drugs Nat. Rev. Drug Discov. 13 2014 759 780
6. R.M. Conry, and et al. Characterization of a messenger RNA polynucleotide vaccine vector Cancer Res. 55 1995 1397 1400
7. F. Martinon, and et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA Eur. J. Immunol. 23 1993 1719 1722
8. D.C. Tang, and et al. Genetic immunization is a simple method for eliciting an immune response Nature 356 1992 152 154
9. I. Hoerr, and et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies Eur. J. Immunol. 30 2000 1 7
10. K.J. Kallen, and A. Thess A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs Ther. Adv. Vaccines 2 2014 10 31
11. S. Van Lint, and et al. The ReNAissanCe of mRNA-based cancer therapy Expert Rev. Vaccines 14 2015 235 251
12. C. Pollard, and et al. Challenges and advances towards the rational design of mRNA vaccines Trends Mol. Med. 19 2013 705 713
13. S. Kreiter, and et al. Tumor vaccination using messenger RNA: prospects of a future therapy Curr. Opin. Immunol. 23 2011 399 406
14. S. Pascolo The messenger's great message for vaccination Expert Rev. Vaccines 14 2015 153 156
15. P.A. Krieg, and D.A. Melton Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs Nucleic Acids Res. 12 1984 7057 7070
16. Y. Li, and M. Kiledjian Regulation of mRNA decapping Wiley Interdiscip. Rev. RNA 1 2010 253 265
17. J. Coller, and R. Parker Eukaryotic mRNA decapping Annu. Rev. Biochem. 73 2004 861 890
18. S.A. Martin, and et al. Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions J. Biol. Chem. 250 1975 9322 9329
19. S.E. Wells, and et al. Circularization of mRNA by eukaryotic translation initiation factors Mol. Cell 2 1998 135 140
20. D.R. Gallie A tale of two termini: a functional interaction between the termini of an mRNA is a prerequisite for efficient translation initiation Gene 216 1998 1 11
21. S. Akira, and et al. Pathogen recognition and innate immunity Cell 124 2006 783 801
22. T. Kawai, and S. Akira Innate immune recognition of viral infection Nat. Immunol. 7 2006 131 137
23. S. Akira, and et al. Toll-like receptors: critical proteins linking innate and acquired immunity Nat. Immunol. 2 2001 675 680
24. H. Kumar, and et al. Toll-like receptors and innate immunity Biochem. Biophys. Res. Commun. 388 2009 621 625
25. A. Yamamoto, and et al. Current prospects for mRNA gene delivery Eur. J. Pharm. Biopharm. 71 2009 484 489
26. F. Heil, and et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 Science 303 2004 1526 1529
27. S.S. Diebold, and et al. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides Eur. J. Immunol. 36 2006 3256 3267
28. L. Alexopoulou, and et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3 Nature 413 2001 732 738
29. K. Kariko, and et al. mRNA is an endogenous ligand for Toll-like receptor 3 J. Biol. Chem. 279 2004 12542 12550
30. S.S. Diebold, and et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA Science 303 2004 1529 1531
31. S. Akira, and K. Takeda Toll-like receptor signalling Nat. Rev. Immunol. 4 2004 499 511
32. M. Yoneyama, and T. Fujita Recognition of viral nucleic acids in innate immunity Rev. Med. Virol. 20 2010 4 22
33. V. Hornung, and et al. 5′-Triphosphate RNA is the ligand for RIG-I Science 314 2006 994 997
34. A. Pichlmair, and et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates Science 314 2006 997 1001
35. M. Schlee, and et al. Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus Immunity 31 2009 25 34
36. A. Schmidt, and et al. 5′-Triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I Proc. Natl. Acad. Sci. U. S. A. 106 2009 12067 12072
37. D. Goubau, and et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5′-diphosphates Nature 514 2014 372 375
38. A. Pichlmair, and et al. Activation of MDA5 requires higher-order RNA structures generated during virus infection J. Virol. 83 2009 10761 10769
39. R. Zust, and et al. Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5 Nat. Immunol. 12 2011 137 143
40. S. Rothenfusser, and et al. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I J. Immunol. 175 2005 5260 5268
41. A. Komuro, and C.M. Horvath RNA- and virus-independent inhibition of antiviral signaling by RNA helicase LGP2 J. Virol. 80 2006 12332 12342
42. T. Satoh, and et al. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses Proc. Natl. Acad. Sci. U. S. A. 107 2010 1512 1517
43. M. Liniger, and et al. Chicken cells sense influenza A virus infection through MDA5 and CARDIF signaling involving LGP2 J. Virol. 86 2012 705 717
44. F. Ikeda, and et al. Involvement of the ubiquitin-like domain of TBK1/IKK-i kinases in regulation of IFN-inducible genes EMBO J. 26 2007 3451 3462
45. A. Israel The IKK complex, a central regulator of NF-kappaB activation Cold Spring Harb. Perspect. Biol. 2 2010 a000158
46. G.C. Sen, and S.N. Sarkar The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses Cur. Top. Microbiol. Immunol. 316 2007 233 250
47. A.J. Sadler, and B.R. Williams Interferon-inducible antiviral effectors Nat. Rev. Immunol. 8 2008 559 568
48. K. Drews, and et al. The cytotoxic and immunogenic hurdles associated with non-viral mRNA-mediated reprogramming of human fibroblasts Biomaterials 33 2012 4059 4068
49. M. Angel, and M. Yanik Innate immune suppression enables frequent transfection with RNA encoding reprogramming proteins PLoS ONE 5 2010 e11756
50. O. Andries, and et al. Innate immune response and programmed cell death following carrier-mediated delivery of unmodified mRNA to respiratory cells J. Control. Release 167 2013 157 166
51. T.D. Kanneganti, and et al. Critical role for cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA J. Biol. Chem. 281 2006 36560 36568
52. A. Sabbah, and et al. Activation of innate immune antiviral responses by Nod2 Nat. Immunol. 10 2009 1073 1080
53. C. Heufler, and et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells Eur. J. Immunol. 26 1996 659 668
54. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252
55. L. Warren, and et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA Cell Stem Cell 7 2010 618 630
56. M.A. Garcia, and et al. The dsRNA protein kinase PKR: virus and cell control Biochimie 89 2007 799 811
57. A. Kumar, and et al. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B Proc. Natl. Acad. Sci. U. S. A. 91 1994 6288 6292
58. S. Balachandran, and et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection Immunity 13 2000 129 141
59. R.H. Silverman Viral encounters with 2′,5′-oligoadenylate synthetase and RNase L during the interferon antiviral response J. Virol. 81 2007 12720 12729
60. E.C. Borden, and et al. Interferons at age 50: past, current and future impact on biomedicine Nat. Rev. Drug Discov. 6 2007 975 990
61. C.X. George, and et al. An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1) J. Interferon Cytokine Res. 34 2014 437 446
62. C.E. Samuel ADARs: viruses and innate immunity Curr. Top. Microbiol. Immunol. 353 2012 163 195
63. J.C. Hartner, and et al. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling Nat. Immunol. 10 2009 109 115
64. W. Qiu, and et al. ADAR1 is essential for intestinal homeostasis and stem cell maintenance Cell Death Dis. 4 2013 e599
65. S. Yang, and et al. Adenosine deaminase acting on RNA 1 limits RIG-I RNA detection and suppresses IFN production responding to viral and endogenous RNAs J. Immunol. 193 2014 3436 3445
66. C.K. Pfaller, and et al. Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old players as modulators of the interferon response Curr. Opin. Immunol. 23 2011 573 582
67. A. Pichlmair, and C.R.E. Sousa Innate recognition of viruses Immunity 27 2007 370 383
68. C. Lorenz, and et al. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway RNA Biol. 8 2011 627 636
69. M. Diken, and et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation Gene Ther. 18 2011 702 708
70. A. Pathak, and et al. Recent trends in non-viral vector-mediated gene delivery Biotechnology J. 4 2009 1559 1572
71. C. Tros de Ilarduya, and et al. Gene delivery by lipoplexes and polyplexes Eur. J. Pharm. Sci. 40 2010 159 170
72. H. Dewitte, and et al. Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment Nano Today 9 2014 743 758
73. M. Fotin-Mleczek, and et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity J. Immunother. 34 2011 1 15
74. B. Scheel, and et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA Eur. J. Immunol. 35 2005 1557 1566
75. J. Rejman, and et al. mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers J. Control. Release 147 2010 385 391
76. C. Lonez, and et al. Cationic lipids activate intracellular signaling pathways Adv. Drug Deliv. Rev. 64 2012 1749 1758
77. L. Rettig, and et al. Particle size and activation threshold: a new dimension of danger signaling Blood 115 2010 4533 4541
78. W. Wang, and et al. Non-viral gene delivery methods Curr. Pharm. Biotechnol. 14 2013 46 60
79. H. Dewitte, and et al. The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy J. Control. Release 194 2014 28 36
80. A. Bonehill, and et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA Mol. Ther. 16 2008 1170 1180
81. G.K. Koski, and et al. Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells J. Immunol. 172 2004 3989 3993
82. S.R. Nallagatla, and et al. 5′-Triphosphate-dependent activation of PKR by RNAs with short stem-loops Science 318 2007 1455 1458
83. E. Grudzien-Nogalska, and et al. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells RNA 13 2007 1745 1755
84. N. Pardi, and et al. In vitro transcription of long RNA containing modified nucleosides Methods Mol. Biol. 969 2013 29 42
85. Y.L. Wang, and et al. Structural and functional insights into 5′-ppp RNA pattern recognition by the innate immune receptor RIG-I Nat. Struct. Mol. Biol. 17 2010 719 781
86. K. Kariko, and et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA Immunity 23 2005 165 175
87. S.R. Nallagatla, and P.C. Bevilacqua Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner RNA 14 2008 1201 1213
88. K. Kariko, and et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability Mol. Ther. 16 2008 1833 1840
89. B.R. Anderson, and et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation Nucleic Acids Res. 38 2010 5884 5892
90. M.S. Kormann, and et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice Nat. Biotechnol. 29 2011 154 157
91. K. Kariko, and et al. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA Nucleic Acids Res. 39 2011 e142
92. H. Hacker, and et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation EMBO J. 17 1998 6230 6240
93. X. He, and et al. Recognition of pathogen-associated nucleic acids by endosomal nucleic acid-sensing toll-like receptors Acta Biochim. Biophys. Sin. 45 2013 241 258
94. A. Kuznik, and et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines J. Immunol. 186 2011 4794 4804
95. R. Rajsbaum, and A. Garcia-Sastre Viral evasion mechanisms of early antiviral responses involving regulation of ubiquitin pathways Trends Microbiol. 21 2013 421 429
96. M. Loiarro, and et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-{kappa}B J. Biol. Chem. 280 2005 15809 15814
97. V.U. Toshchakov, and et al. Differential involvement of BB loops of toll-IL-1 resistance (TIR) domain-containing adapter proteins in TLR4- versus TLR2-mediated signal transduction J. Immunol. 175 2005 494 500
98. K. Clark, and et al. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation J. Biol. Chem. 284 2009 14136 14146
99. J.P. Awe, and et al. BAY11 enhances OCT4 synthetic mRNA expression in adult human skin cells Stem Cell Res. Ther. 4 2013 15
100. T.L. Rowland, and et al. Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B Int. Immunopharmacol. 1 2001 49 61
101. N. Auphan, and et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis Science 270 1995 286 290
102. R.I. Scheinman, and et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids Science 270 1995 283 286
103. D. Chauhan, and et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays Oncogene 21 2002 1346 1358
104. S. Bhattacharyya, and et al. TAK1 targeting by glucocorticoids determines JNK and IkappaB regulation in Toll-like receptor-stimulated macrophages Blood 115 2010 1921 1931
105. N. Harii, and et al. Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis Mol. Endocrinol. 19 2005 1231 1250
106. A.L. Schwartz, and et al. Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration Clin. Cancer Res. 15 2009 4114 4122
107. F.X. Zhu, and et al. A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation Proc. Natl. Acad. Sci. U. S. A. 99 2002 5573 5578
108. F.X. Zhu, and et al. Antagonism of host antiviral responses by Kaposi's sarcoma-associated herpesvirus tegument protein ORF45 PLoS ONE 5 2010 e10573
109. P.K. Mandal, and D.J. Rossi Reprogramming human fibroblasts to pluripotency using modified mRNA Nat. Protoc. 8 2013 568 582
110. H. Kambara, and et al. Negative regulation of the interferon response by an interferon-induced long non-coding RNA Nucleic Acids Res. 42 2014 10668 10680
111. A. Quintas-Cardama, and et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms Blood 115 2010 3109 3117
112. A. Quintas-Cardama, and S. Verstovsek Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance Clin. Cancer Res. 19 2013 1933 1940
113. A. Gupta, and P.C. Rath Curcumin, a natural antioxidant, acts as a noncompetitive inhibitor of human RNase L in presence of its cofactor 2-5A in vitro Biomed. Res. Int. 2014 2014 817024
114. Y. Xiang, and et al. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus J. Virol. 76 2002 5251 5259
115. K. Carroll, and et al. Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase J. Biol. Chem. 268 1993 12837 12842
116. Y. Hu, and T.W. Conway 2-Aminopurine inhibits the double-stranded RNA-dependent protein kinase both in vitro and in vivo J. Interferon Res. 13 1993 323 328
117. T. Sugiyama, and et al. Mechanism of inhibition of lipopolysaccharide-induced interferon-beta production by 2-aminopurine Mol. Immunol. 52 2012 299 304
118. N.V. Jammi, and et al. Small molecule inhibitors of the RNA-dependent protein kinase Biochem. Biophys. Res. Commun. 308 2003 50 57
119. S. Ingrand, and et al. The oxindole/imidazole derivative C16 reduces in vivo brain PKR activation FEBS Lett. 581 2007 4473 4478
120. S. Nekhai, and et al. A cell-permeable peptide inhibits activation of PKR and enhances cell proliferation Peptides 21 2000 1449 1456
121. B.K. Jha, and et al. Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity J. Biol. Chem. 286 2011 26319 26326
122. B.K. Jha, and et al. Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy Mol. Ther. 21 2013 1749 1757
123. G.L. Smith, and et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity J. Gen. Virol. 94 2013 2367 2392
124. S. Kettle, and et al. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever J. Gen. Virol. 78 1997 677 685
125. A. Mantovani, and et al. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines Trends Immunol. 22 2001 328 336
126. C. Myskiw, and et al. Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways J. Virol. 83 2009 6757 6768
127. M. Yoneyama, and et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses Nat. Immunol. 5 2004 730 737
128. I.C. Allen, and et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA Immunity 30 2009 556 565
129. M. Schmolke, and et al. RIG-I detects mRNA of intracellular Salmonella enterica serovar Typhimurium during bacterial infection MBio 5 2014 e01006 e01014
130. K. Kariko, and et al. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through Toll-like receptor 3 J. Immunol. 172 2004 6545 6549
131. G.F. Jirikowski, and et al. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA Science 255 1992 996 998
132. L. Zangi, and et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction Nat. Biotechnol. 31 2013 898 907
133. K. Takahashi, and et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors Cell 131 2007 861 872
134. E. Yakubov, and et al. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors Biochem. Biophys. Res. Commun. 394 2010 189 193
135. J. Lee, and et al. Activation of innate immunity is required for efficient nuclear reprogramming Cell 151 2012 547 558
136. A.M. Krieg, and et al. CpG motifs in bacterial DNA trigger direct B-cell activation Nature 374 1995 546 549
137. M.D. Halpern, and et al. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha Cell Immunol. 167 1996 72 78
138. Z.K. Ballas, and et al. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA J. Immunol. 157 1996 1840 1845
139. D.M. Anderson, and et al. Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: methods and evidence for nonviral mRNA gene delivery to the central nervous system Hum. Gene Ther. 14 2003 191 202
140. K. Okumura, and et al. Bax mRNA therapy using cationic liposomes for human malignant melanoma J. Gene Med. 10 2008 910 917
141. K. Kariko, and et al. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin Mol. Ther. 20 2012 948 953
142. L.E. Mays, and et al. Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism J. Clin. Invest. 123 2013 1216 1228
143. M. Baba, and et al. Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles J. Control. Release 201 2015 41 48
144. J.R. Plews, and et al. Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach PLoS ONE 5 2010 e14397
145. G. Tavernier, and et al. Activation of pluripotency-associated genes in mouse embryonic fibroblasts by non-viral transfection with in vitro-derived mRNAs encoding Oct4, Sox2, Klf4 and cMyc Biomaterials 33 2012 412 417
146. L. Warren, and et al. Feeder-free derivation of human induced pluripotent stem cells with messenger RNA Sci. Rep. 2 2012 657
147. N. Yoshioka, and et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA Cell Stem Cell 13 2013 246 254
148. A.K. El-Sayed, and et al. Pluripotent state induction in mouse embryonic fibroblast using mRNAs of reprogramming factors Int. J. Mol. Sci. 15 2014 21840 21864
149. M.C. Courreges, and et al. Phenylmethimazole blocks dsRNA-induced IRF3 nuclear translocation and homodimerization Molecules 7 2012 12356 12377